



News Release

For Immediate Release
Lori Prochaska, Public Relations Manager
402-691-7452
lprochaska@streck.com

December 14, 2007

Streck adds markers to flow cytometry controls

CD-Chex® Plus and CD-Chex® Plus BC now assayed for CD11c, CD15 and CD10

Omaha, NE — Streck Inc., a leading independent developer and manufacturer of controls for the clinical laboratory, announces the addition of markers to the assays of CD-Chex Plus and CD-Chex Plus BC whole blood process controls.

CD-Chex Plus and CD-Chex Plus BC determine the accuracy and reproducibility of all the steps involved in the immunophenotyping process. Streck is the first to offer a commercial process control with assay values for CD11c, CD15, and CD10.

Clinical flow cytometry labs that routinely analyze leukemia and lymphoma patient samples are required to run a positive control at least monthly for leukemia and lymphoma immunophenotyping. The addition of these markers to Streck's CD-Chex Plus and CD-Chex Plus BC allows laboratories to validate their testing procedures.

Both CD-Chex Plus and CD-Chex Plus BC offer an open-vial stability of 30 days and a closed-vial stability of 90 days.

STATS®, Streck's free interlaboratory quality control program, is available for CD-Chex Plus and CD-Chex Plus BC customers. *STATS* produces relevant peer group comparison reports and graphs with a quick turnaround time. Data can be submitted by mail, fax or e-mail. The reports include customer data, peer group averages and computer-generated Levey-Jennings graphs.

Over the past 30 years, Streck has developed a reputation for excellence that includes consistent, high-quality controls and responsive customer service and technical service teams. For more information, call 800-843-0912 or consult Streck online at www.streck.com.